CA-VERIMATRIX
1.9.2022 17:46:43 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it will highlight its powerful content protection, anti-piracy and enterprise cybersecurity technologies for streaming services providers, broadcasters, telcos and operators from September 9-12 during this year’s IBC conference at RAI Amsterdam.
The company’s IBC showcase follows a fast-growing number of technology partnerships that underscore the appeal of the cloud-based Verimatrix Streamkeeper solution that’s designed to enable battle-ready, yet streamlined and cost-effective protections for content delivered via nearly any platform type. The IBC conference serves as one of the media and entertainment industry’s most notable venues to feature Verimatrix’s unique zero-code telemetry approach that makes anti-piracy and cybersecurity not only simple and fast, but also cost-effective and designed to encourage integration with other related M&E providers.
IBC Show Highlights:
- Product demos - Verimatrix XTD (Extended Threat Defense), Verimatrix Streamkeeper, Verimatrix Secure Delivery Platform and Verimatrix VCAS (IPTV/DVB)
- 3D hologram – A holographic presentation of Verimatrix Counterspy, the company’s proprietary anti-piracy and app protection security agent that uses proprietary zero code technology
- Partner recognition – Technology partners are critical to Verimatrix’s success, and the company will feature key partners on its partner wall, during demos and in booth videos
The company is set to host two in-booth mixers at its IBC Booth 1.C23 on September 9 and 10 with TiVo, a leader in DVR and advanced television, as well as The Goose House, a popular esports community that Verimatrix sponsors. Verimatrix is also sponsoring a Media and Entertainment Services Alliance (MESA) networking event scheduled for 8-10 p.m. on September 9 at Café Black.
“Today’s countless ways of delivering and consuming entertainment require a modern approach to anti-piracy and cyberattack prevention, but they must be offered as business enablers and value providers versus costs centers. Verimatrix Streamkeeper and Verimatrix XTD are two new solutions engineered to do just that,” said Asaf Ashkenazi, CEO at Verimatrix. “Our theme for IBC 2022 is ‘STREAM ON! Game changing security for streaming & beyond’ and we are excited to showcase a stunning new booth design where we will showcase our latest products alongside our award-winning, legacy content security solutions.”
Verimatrix Streamkeeper stands as a cybersecurity and anti-piracy gamechanger. Its users can implement a comprehensive set of content protection and anti-piracy solutions such as Multi-DRM, Watermarking, App Shield and other countermeasures that allow users to hunt down and take out OTT pirates who often take advantage of premium content that’s left unprotected. Streamkeeper includes Verimatrix's Counterspy technology – the autonomous injection of an anti-piracy and app protection security agent that uses proprietary zero code technology that brings deep, defensive countermeasures as well as the monitoring of clients without the hassle of a huge integration effort.
Verimatrix XTD defends against endpoint attacks by monitoring apps, APIs and unmanaged devices; illuminating blind spots and preventing firewall intrusions -- threats that are not typically covered by existing cybersecurity solutions.
Verimatrix Streamkeeper info is available at www.verimatrix.com/products/streamkeeper.
Verimatrix XTD info is available at www.verimatrix.com/products/extended-threat-defense.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom